Fatter ikke at vi er gået 5 sider uden noget forskning til at bakke up de mange påstande der er blevet fremlagt.
Synes i det hele taget at denne tråd er ganske trist, fordi begge akser fremlægger deres værste sider. De ignorante som stille dumme spørgsmål, og er som selvvanligt ganske uvillige til selv at lave lidt research. Og omvendt har vi modstanderne af doping som tror de har alle svarene, dog uden beviserne. Det er pisse trist!
Clin Endocrinol (Oxf). 1993 Apr;38(4):393-8.
The effects of oxandrolone on the growth hormone and gonadal axes in boys with constitutional delay of growth and puberty.
Malhotra A, Poon E, Tse WY, Pringle PJ, Hindmarsh PC, Brook CG.
Endocrine Unit, Middlesex Hospital, London, UK.
OBJECTIVE: We studied the effects of oxandrolone on serum concentrations of LH, FSH, testosterone, GH, SHBG, DHEAS, IGF-I and insulin in boys with constitutional delay of growth and puberty. DESIGN: Ten boys with constitutional delay of growth and puberty, mean age 13.8 years (range 12.4-15.5) were studied. Twenty-four-hour serum concentration profiles of GH, LH and FSH were constructed by drawing blood samples at 20-minute intervals. Three study occasions over a period of 6 months were chosen to assess hormone concentrations before, during and 6 weeks after a 3-month course of oxandrolone (2.5 mg once daily) therapy. RESULTS: Growth velocity increased during oxandrolone treatment and stayed higher after therapy (pre 3.9 +/- 0.5; on 6.3 +/- 0.8; post 6.4 +/- 0.9 cm/year (mean +/- SEM) two way ANOVA, F = 5.3, P = 0.02). Oxandrolone had androgenic effects, suppressing mean serum LH concentrations from 1.7 +/- 0.3 to 1.1 +/- 0.2 U/I and serum testosterone concentrations from 1.9 +/- 0.6 to 0.8 +/- 0.1 nmol/l. SHBG concentrations were also reduced from 130.9 +/- 14.6 to 30.7 +/- 7.3 nmol/l. Serum GH concentration fell slightly from 5.9 +/- 0.6 to 4.8 +/- 0.5 mU/l. After cessation of treatment, there was a significant 'rebound' in mean 24-hour serum LH (2.6 U/l +/- 0.4) and testosterone concentrations (3.2 +/- 0.9 nmol/l) but no change in serum GH concentrations. SHBG values also rose but not to the same extent as those observed before therapy (82.0 +/- 8.4 nmol/l). There were no statistically significant differences in serum concentrations of FSH, DHEAS, IGF-I and insulin over the study period. In a stepwise multiple regression analysis of factors that might influence the growth rate observed, the 24-hour mean serum testosterone concentration and the treatment (on or off) with oxandrolone were the main influences. The relationship was described by the equation Height velocity = 0.69 (24-hour mean serum testosterone concentration)+1.70 (treatment regimen)+3.37 (adjusted R2 = 0.35, F = 8.39, P = 0.001). CONCLUSIONS: Oxandrolone has an androgenic action as shown by changes in serum LH, testosterone and SHBG concentrations and by the lack of effect on FSH. No effect of oxandrolone on the GH axis was documented. We suggest that the growth promoting effects of oxandrolone are related in part to the mild androgenic effects of the steroid and the growth acceleration following oxandrolone withdrawal may reflect increasing total serum testosterone concentrations and decreasing levels of SHBG and progress in puberty.
PMID: 8319371 [PubMed - indexed for MEDLINE]
Dette studie indikere at det ikke vil lukke dig ned, men vil undertrykke din egn produktion.
Clin Endocrinol (Oxf). 1997 Feb;46(2):209-16. Related Articles, Links
Effect of low dose oxandrolone and testosterone treatment on the pituitary-testicular and GH axes in boys with constitutional delay of growth and puberty.
Crowne EC, Wallace WH, Moore C, Mitchell R, Robertson WH, Holly JM, Shalet SM.
Department of Endocrinology, Christie Hospital Trust, Manchester, UK.
OBJECTIVE: To investigate the effect of low dose oxandrolone and testosterone on the pituitary-testicular and GH-IGF-I axes. DESIGN: Prospective double-blind placebo-controlled trial. PATIENTS: Sixteen boys with constitutional delay of growth and puberty (CDGP) with testicular volumes 4-6 ml were randomized to 3 months treatment: Group 1 (n = 5), daily placeb Group 2 (n = 5), 2.5 mg oxandrolone daily or Group 3 (n = 6), 50 mg testosterone monthly intramuscular injections with assessment (growth, pubertal development and overnight hormone profiles) at 0, 3, 6 and 12 months. MAIN OUTCOME MEASURES: LH and GH profiles (15-minute samples) were analysed by peak detection (Pulsar), Fourier transformation and autocorrelation. Testosterone levels were measured hourly and insulin, SHBG, IGF-I, and IGFBP-3 levels at 0800 h. Statistical analysis was by multivariate analysis of variance for repeated measures. RESULTS: LH and testosterone parameters increased significantly with time in all 16 (LH AUC, P < 0.001; peak amplitude, P = 0.02; number of peaks, P = 0.02; testosterone AUC, P = 0.02; morning testosterone, P = 0.002). In Group 2, however, LH and testosterone parameters decreased at 3 months followed by a rebound increase at 6 and 12 months. SHBG levels were markedly reduced at 3 months (P = 0.006) and a wider range of dominant GH frequencies was present although GH AUC was not increased until 6 months, with an increase in GH pulse frequency but not amplitude. IGF-I levels were increased at both 3 and 12 months. In Group 3, pituitary-testicular suppression was not apparent, but GH levels increased with an increase in GH amplitude at 3 and 12 months. CONCLUSION: Oxandrolone transiently suppressed the pituitary-testicular axis and altered GH pulsatility. Testosterone increased GH via amplitude modulation
Pretty much sammen konklusion.
Selv i høje doser synes Oxandrolon ikke at nedsætte kroppens egen produktion af testosteron, hvilket jo i sagens natur er en fordel, hvis man som man ønsker at beholde sin frugtbarhed.
http://www.antidoping.dk/visArtikel.asp ... print=trueMere ADD bullshit. Synes ikke det er forsvarligt at et stats sponsoreret organ som ADD kan slippe af sted med at skrive hormon profiler uden kilde angivelser og uden signatur.
Alle steroider stopper højdevæksten ved at smelte knoglernes vækstzoner sammen før tid. Jeg har arbejdet på en børneafdeling hvor vi netop gav steroider herunder også testosteron for at stoppe væksten hos børn som ellers ville blive sygeligt høje.
http://www.antidoping.dk/visEkspertpane ... maalID=717Flere ADD påstande der ingen kilder eller forfatter har.
Anavar was the old U.S. brand name for the oral steroid oxandrolone, first produced in 1964 by the drug manufacturer Searle. It was designed as an extremely mild anabolic, one that could even be safely used as a growth stimulant in children. One immediately thinks of the standard worry, "steroids will stunt growth". But it is actually the excess estrogen produced by most steroids that is the culprit, just as it is the reason why women stop growing sooner and have a shorter average stature than men. Oxandrolone will not aromatize, and therefore the anabolic effect of the compound can actually promote linear growth.
Kunne ikke finde en kilde der ikke kom fra en krudt relateret side, så tag dette citat med en gran salt. Dog er udsagnet i overensstemmelse med det de studier der er blevet lavet.
Det er det ren videnskabelige. Mange bodybuildere vil dog påstå at de kan tolererer moderate doser over længere tid uden blive lukket ned. Vi må konkludere at som med alle medikamenter reagere folk forskelligt på dem!
Håber vi kan lade det her ligge nu, og fremover forsøger at holde os på et mere videnskabeligt niveau når vi snakker om doping. Fordi forsætter vi sådan med at have tråde i doping sektionen der indeholder udtalelser som ”jeg kender ham og ham som opnået det og det, osv.,” og ikke mindst posts med doserings beskrivelser (skam jer mods!), så er der fandme intet at sige til at ekstrabladet sidestiller os med bodyhouse.